ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension

Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Age Range:18 - Any
Start Date:April 1, 2017
End Date:December 2020
Contact:Berta Grigorian

Use our guide to learn which trials are right for you!

A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)

mTOR activation has been shown to be relevant in the development and progression of pulmonary
hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension
in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in
lung tissue.

Inclusion Criteria:

- Male or female age >18 year old with a current diagnosis of WHO Group 1 PAH including
idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial
hypertension (HPAH), drug and toxin induced PAH, or PAH associated with connective
tissue disease, or congenital heart defects (repaired greater than 1 year prior to

- Must meet following hemodynamic definition prior to initiation of study drug

- Mean PAP of ≥ 25 mm Hg

- PCWP or left ventricular end diastolic pressure (LVEDP) of ≤ 12 mm

- PVR >5 mmHg/L/min (Woods unit)

- Functional class III or IV according to the WHO set forth at the Dana Point
Classification 2008 Meeting

- On 2 or more specific standard PAH therapies (for ≥ 12 consecutive weeks and at stable
dose for ≥ 8 consecutive weeks) unless documented inability to tolerate 2 standard

- Meet the following criteria determined by pulmonary function tests completed no more
than 24 weeks prior to screening, performed with or without bronchodilation:

- Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal

- FEV1:forced vital capacity (FVC) ratio ≥ 0.60

- 6MWD ≥150 meters and ≤450 meters

- Negative serum pregnancy test

- Female of childbearing age either surgically sterilized or using acceptable method of

- Ability to provide written informed consent by the patient or legal guardian

Exclusion criteria:

- History of heart disease including left ventricular ejection fraction (LVEF) ≤ 40% or
clinically significant valvular constrictive or atherosclerotic heart disease
(myocardial infarction, angina, cerebrovascular accident)

- History of malignancy in 2 years prior to enrollment

- Pulmonary hypertension (PH) belonging to groups 2 to 5 of the 2013 Nice classification

- Current or recent (< 3 months) use of inotropic or vasopressor agents for the
treatment of PAH

- Recent (< 3 months) PAH related hospital admission

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition including macrolide (eg, azithromycin, clarithromycin, dirithromycin, and
erythromycin) and ketolide antibiotics

- Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy

- Uncontrolled hyperlipidemia (serum triglyceride ≥300 mg/dL)

- Serum cholesterol ≥350 mg/dL

- Surgery within 3 months of start date of study drug

- Baseline cytopenias:

- Absolute Neutrophil Count ≤ 1.5 x 109/L

- Hemoglobin ≤ 9 g/dL

- Platelet count < 100,000/mm3

- Baseline liver disease: ALT/AST, total bilirubin, alkaline phosphatase >1.5 x ULN

- Baseline renal disease: creatinine >1.5 ULN and/or creatinine clearance (Cockroft
formula) ≤ 60 mL/min

- Inability to attend scheduled clinic visits

- Prior use of study drug within previous 6 months from enrollment

- Previous lung transplant

- Naïve to available standard PAH therapy

- Concomitant genetic or acquired immunosuppressive diseases (such as HIV, AIDS)

- Uncontrolled intercurrent illness that in the opinion of the investigator would limit
compliance and tolerance to study requirements (eg, ongoing or active infection,
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,
diabetes, uncontrolled hypertension, coronary artery disease, or psychiatric
illness/social situations)

- Concomitant enrollment in another investigational treatment protocol for PAH

- Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to
receiving the first dose of ABI-009
We found this trial at
1000 W Carson St
Torrance, California 90502
Phone: 310-222-3560
Torrance, CA
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
(703) 776-4001
Phone: 703-776-3697
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Falls Church, VA
Click here to add this to my saved trials
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Phone: 317-962-9904
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
Indianapolis, IN
Click here to add this to my saved trials
Bethesda, Maryland 20892
Phone: 301-827-6135
Bethesda, MD
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Phone: 412-647-4463
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Pittsburgh, PA
Click here to add this to my saved trials
Tucson, Arizona 85721
(520) 621-2211
Phone: 520-626-8305
University of Arizona The University of Arizona is a premier, public research university. Established in...
Tucson, AZ
Click here to add this to my saved trials